GSK Biologicals' HPV vaccine 580299

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, PapillomavirusPapillomavirus Vaccines

Phase 3

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

CompletedNCT01381575

GlaxoSmithKlineInfections, Papillomavirus

Start: 2011-06-29End: 2014-11-13Updated: 2020-06-09

Phase 4

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

CompletedNCT01031069

GlaxoSmithKlineInfections, Papillomavirus, Papillomavirus Vaccines

Start: 2010-10-26End: 2017-04-19Updated: 2020-07-21

Related Papers

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.

2020-05-2510 citations

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

The Journal of Infectious Diseases2019-01-0816 citations

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

The Journal of Infectious Diseases2016-02-0346 citations

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Human Vaccines & Immunotherapeutics2015-07-1593 citations

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

Human Vaccines & Immunotherapeutics2014-02-2799 citations

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

2012-12-1348 citations